DL‑3‑n‑butylphthalide therapy for Parkinson's disease: A randomized controlled trial

Zhou,Haiyan; Ye,Ming; Xu,Wenfang; Yu,Meiling; Liu,Xiaolin; Chen,Yuhua

doi:10.3892/etm.2019.7397

DL‑3‑n‑butylphthalide therapy for Parkinson's disease: A randomized controlled trial

Authors:
- Haiyan Zhou
- Ming Ye
- Wenfang Xu
- Meiling Yu
- Xiaolin Liu
- Yuhua Chen
View Affiliations

Affiliations: Department of Gerontology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, P.R. China, Department of Neurology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, P.R. China, Department of Pharmacy, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, P.R. China, Department of Neurology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, Anhui 230001, P.R. China
Published online on: March 14, 2019 https://doi.org/10.3892/etm.2019.7397
Pages: 3800-3806

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Currently available treatments for Parkinson's disease (PD) do not delay or prevent disease development and progression. DL‑3‑n‑butylphthalide (NBP), isolated from Apium graveolens seeds, alleviates oxidative damage and mitochondrial dysfunction. It has been revealed to reduce the loss of dopamine neurons in pre‑clinical PD models, and has been approved for the treatment of ischemic stroke patients. The purpose of the present study was to examine whether NBP has the capacity provide a benefit for PD patients and to slow disease progression. A randomized, controlled trial was performed between September 2014 and December 2016. Pairs of patients matched by age, gender and off‑medication Unified PD Rating Scale motor subscale (UPDRS‑III) scores, were randomly assigned to an NBP treatment group and a control group. All patients continued their originally prescribed medication regimen and those in the NBP group were administered NBP at 200 mg three times daily for 24 weeks. Primary outcome measures were changes in UPDRS‑III, including tremor score and non‑tremor score, the Pittsburgh sleep quality index (PSQI) and the PD 39‑items questionnaire (PDQ) scores. Assessments were completed by blinded evaluators at baseline and 12, 24 and 48 weeks after randomization. All patients were monitored for adverse events (AEs). A total of 103 patients were enrolled in the present study. The NBP group exhibited significantly greater improvements in the non‑tremor, PSQI and PDQ‑39 scores than the control group, which generally exhibited no improvement. NBP‑associated AEs were uncommon and primarily consisted of mild gastrointestinal symptoms. In conclusion, over the 6‑month treatment period, NBP was safe and effective for improving the symptoms and impairing the progression of patients with PD (Trial registry number, ChiCTR1800018892).

View Figures

View References

1	Marras C and Chaudhuri KR: Nonmotor features of Parkinson's disease subtypes. Mov Disord. 31:1095–1102. 2016.
2	Liu CL, Liao SJ, Zeng JS, Lin JW, Li CX, Xie LC, Shi XG and Huang RX: dl-3n-butylphthalide prevents stroke via improvement of cerebral microvessels in RHRSP. J Neurol Sci. 260:106–113. 2007.
3	Zhao Y, Lee JH, Chen D, Gu X, Caslin A, Li J, Yu SP and Wei L: DL-3-n-butylphthalide induced neuroprotection, regenerative repair, functional recovery and psychological benefits following traumatic brain injury in mice. Neurochem Int. 111:82–92. 2017.
4	Jia J, Wei C, Liang J, Zhou A, Zuo X, Song H, Wu L, Chen X, Chen S, Zhang J, et al: The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischemic small vessel disease: A multicentre, randomized, double-blind, placebo-controlled trial. Alzheimers Dement. 12:89–99. 2016.
5	Cui LY, Zhu YC, Gao S, Wang JM, Peng B, Ni J, Zhou LX, He J and Ma XQ: Ninety-day administration of dl-3-n-butylphthalide for acute ischemic stroke: A randomized, double-blind trial. Chin Med J (Engl). 126:3405–3410. 2013.
6	Huang JZ, Chen YZ, Su M, Zheng HF, Yang YP, Chen J and Liu CF: dl-3-n-Butylphthalide prevents oxidative damage and reduces mitochondrial dysfunction in an MPP(+)-induced cellular model of Parkinson's disease. Neurosc Lett. 475:89–94. 2010.
7	Xiong N, Huang J, Chen C, Zhao Y, Zhang Z, Jia M, Zhang Z, Hou L, Yang H, Cao X, et al: Dl-3-n-butylphthalide, a natural antioxidant, protects dopamine neurons in rotenone models for Parkinson's disease. Neurobiol Aging. 33:1777–1791. 2012.
8	Hughes AJ, Daniel SE, Kilford L and Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 55:181–184. 1992.
9	Corcos DM, Robichaud JA, David FJ, Leurgans SE, Vaillancourt DE, Poon C, Rafferty MR, Kohrt WM and Comella CL: A two-year randomized controlled trial of progressive resistance exercise for Parkinson's disease. Mov Disord. 28:1230–1240. 2013.
10	Schiess MC, Zheng H, Soukup VM, Bonnen JG and Nauta HJ: Parkinson's disease subtypes: Clinical classification and ventricular cerebrospinal fluid analysis. Parkinsonism Relat Disord. 6:69–76. 2000.
11	Thomas S, Reading J and Shephard RJ: Revision of the physical activity readiness questionnaire (PAR-Q). Can J Sport Sci. 17:338–345. 1992.
12	Volta M, Milnerwood AJ and Farrer MJ: Insights from late-onset familial parkinsonism on the pathogenesis of idiopathic Parkinson's disease. Lancet Neurol. 14:1054–1064. 2015.
13	Calabresi P and Di Filippo M: Multitarget disease-modifying therapy in Parkinson's disease? Lancet Neurol. 14:975–976. 2015.
14	Spiegel J, Möllers MO, Jost WH, Fuss G, Samnick S, Dillmann U, Becker G and Kirsch CM: FP-CIT and MIBG scintigraphy in early Parkinson's disease. Mov Disord. 20:552–561. 2005.
15	Ahlskog JE: Diagnosis and differential diagnosis of Parkinson's disease and parkinsonism. Parkinsonism Relat Disord. 7:63–70. 2000.
16	Chiaravalloti A, Stefani A, Tavolozza M, Pierantozzi M, Di Biagio D, Olivola E, Di Pietro B, Stampanoni M, Danieli R, Simonetti G, et al: Different patterns of cardiac sympathetic denervation in tremor-type compared to akinetic-rigid-type Parkinson's disease: Molecular imaging with ¹²³I-MIBG. Mol Med Rep. 6:1337–1342. 2012.
17	Schillaci O, Chiaravalloti A, Pierantozzi M, Di Pietro B, Koch G, Bruni C, Stanzione P and Stefani A: Different patterns of nigrostriatal degeneration in tremor type versus the akinetic-rigid and mixed types of Parkinson's disease at the early stages: Molecular imaging with 123I-FP-CIT SPECT. Int J Mol Med. 28:881–886. 2011.
18	Shannon KM, Keshavarzian A, Dodiya HB, Jakate S and Kordower JH: Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov Disord. 27:716–719. 2012.
19	Espay AJ, LeWitt PA and Kaufmann H: Norepinephrine deficiency in Parkinson's disease: The case for noradrenergic enhancement. Mov Disord. 29:1710–1719. 2014.
20	Zhao J, Liu J, Xu E, Liu Y, Xie A and Xiong H: dl-3-n-Butylphthalide attenuation of methamphetamine-induced neurotoxicity in SH-SY5Y neuroblastoma cells. Life Sci. 165:16–20. 2016.
21	Zhou J, Zhang YH, Song HZ, Ji H, Wang XL, Wang L, Qian J, Ling JJ and Ping FF: 5d, a novel analogue of 3-n-butylphthalide, decreases NADPH oxidase activity through the positive regulation of CK2 after ischemia/reperfusion injury. Oncotarget. 7:39444–39457. 2016.
22	Liu K, Huang J, Chen R, Zhang T, Shen L, Yang J and Sun X: Protection against neurotoxicity by an autophagic mechanism. Braz J Med Biol Res. 45:401–407. 2012.
23	Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, Knapp DJ and Crews FT: Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia. 55:453–462. 2007.
24	Pal GD, Shaikh M, Forsyth CB, Ouyang B, Keshavarzian A and Shannon KM: Abnormal lipopolysaccharide binding protein as marker of gastrointestinal inflammation in Parkinson disease. Front Neurosci. 9:3062015.
25	Hand TW, Vujkovic-Cvijin I, Ridaura VK and Belkaid Y: Linking the microbiota, chronic disease, and the immune system. Trends Endocrinol Metab. 27:831–843. 2016.
26	Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, Challis C, Schretter CE, Rocha S, Gradinaru V, et al: Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell. 167:1469–1480.e12. 2016.
27	McCann H, Cartwright H and Halliday GM: Neuropathology of α-synuclein propagation and braak hypothesis. Mov Disord. 31:152–160. 2016.
28	Yang Q, Hu YD, Wang XF and Zheng FS: Dl-3n-butylphthalide reduces epileptiform activity through GluA2-lacking calcium-permeable AMPARs in epilepsy models. Oncotarget. 8:98242–98257. 2017.